Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer

BACKGROUND: Despite the introduction of trastuzumab, pathologic complete response (pCR) is not attained in approximately 30–40% of Human epithelial growth factor receptor-2-positive breast cancer. Tumor-infiltrating lymphocytes (TIL) have been suggested as a predictive marker of treatment response,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Junyoung, Ham, Baknoon, Seo, Jeong-Han, Lee, Sae Byul, Park, In Ah, Gong, Gyungyub, Kim, Sung-Bae, Lee, Hee Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972050/
https://www.ncbi.nlm.nih.gov/pubmed/36865681
http://dx.doi.org/10.1177/17588359231157654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972050/
https://www.ncbi.nlm.nih.gov/pubmed/36865681
http://dx.doi.org/10.1177/17588359231157654

Ejemplares similares